WallStreetZenWallStreetZen

NASDAQ: TLX
Telix Pharmaceuticals Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for TLX

Based on 2 analysts offering 12 month price targets for Telix Pharmaceuticals Ltd

Min Forecast
$22.00+62.96%
Avg Forecast
$22.50+66.67%
Max Forecast
$23.00+70.37%

Should I buy or sell TLX stock?

Based on 2 analysts offering ratings for Telix Pharmaceuticals Ltd.

Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although TLX's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates TLX as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their TLX stock forecasts and price targets.

TLX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-07-03
lockedlocked$00.00+00.00%2025-06-12

1 of 1

Forecast return on equity

Is TLX forecast to generate an efficient return?

Company
N/A
Industry
150.95%
Market
91.07%

Forecast return on assets

Is TLX forecast to generate an efficient return on assets?

Company
N/A
Industry
47.18%

TLX earnings per share forecast

What is TLX's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$0.47
Avg 2 year Forecast
$0.94
Avg 3 year Forecast
$0.72

TLX revenue forecast

What is TLX's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$748.1M+53.78%
Avg 2 year Forecast
$984.6M+102.39%
Avg 3 year Forecast
$1.1B+129.35%
TLX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

TLX revenue growth forecast

How is TLX forecast to perform vs Biotechnology companies and vs the US market?

Company
32.19%
Industry
62.75%
Market
10.65%
TLX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
TLX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

TLX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TLX$13.50$22.50+66.67%Buy
ABVX$70.84$81.83+15.53%Strong Buy
PCVX$34.82$129.40+271.63%Strong Buy
MRUS$66.16$91.38+38.11%Strong Buy
RNA$36.88$68.18+84.88%Strong Buy
View Top Biotech Stocks

Telix Pharmaceuticals Stock Forecast FAQ

Is Telix Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: TLX) stock is to Buy TLX stock.

Out of 2 analysts, 0 (0%) are recommending TLX as a Strong Buy, 2 (100%) are recommending TLX as a Buy, 0 (0%) are recommending TLX as a Hold, 0 (0%) are recommending TLX as a Sell, and 0 (0%) are recommending TLX as a Strong Sell.

If you're new to stock investing, here's how to buy Telix Pharmaceuticals stock.

What is TLX's earnings growth forecast for 2025-2027?

(NASDAQ: TLX) Telix Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 7.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.59%.

Telix Pharmaceuticals's earnings in 2025 is $31,395,597.On average, 5 Wall Street analysts forecast TLX's earnings for 2025 to be $155,981,610, with the lowest TLX earnings forecast at $53,555,918, and the highest TLX earnings forecast at $271,126,833. On average, 5 Wall Street analysts forecast TLX's earnings for 2026 to be $315,310,465, with the lowest TLX earnings forecast at $110,459,080, and the highest TLX earnings forecast at $826,769,478.

In 2027, TLX is forecast to generate $241,001,629 in earnings, with the lowest earnings forecast at $110,459,080 and the highest earnings forecast at $418,405,606.

What is TLX's revenue growth forecast for 2025-2027?

(NASDAQ: TLX) Telix Pharmaceuticals's forecast annual revenue growth rate of 32.19% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 62.75%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.65%.

Telix Pharmaceuticals's revenue in 2025 is $492,583,018.On average, 4 Wall Street analysts forecast TLX's revenue for 2025 to be $250,397,345,494, with the lowest TLX revenue forecast at $175,238,309,632, and the highest TLX revenue forecast at $280,164,393,945. On average, 4 Wall Street analysts forecast TLX's revenue for 2026 to be $329,556,338,952, with the lowest TLX revenue forecast at $221,075,480,608, and the highest TLX revenue forecast at $372,280,572,217.

In 2027, TLX is forecast to generate $373,448,760,670 in revenue, with the lowest revenue forecast at $264,064,146,217 and the highest revenue forecast at $453,417,787,381.

What is TLX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: TLX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 47.18%.

What is TLX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year TLX price target, the average TLX price target is $22.50, with the highest TLX stock price forecast at $23.00 and the lowest TLX stock price forecast at $22.00.

On average, Wall Street analysts predict that Telix Pharmaceuticals's share price could reach $22.50 by Jul 3, 2026. The average Telix Pharmaceuticals stock price prediction forecasts a potential upside of 66.67% from the current TLX share price of $13.50.

What is TLX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: TLX) Telix Pharmaceuticals's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that TLX's EPS will be $0.47 for 2025, with the lowest EPS forecast at $0.16, and the highest EPS forecast at $0.81. On average, analysts forecast that TLX's EPS will be $0.94 for 2026, with the lowest EPS forecast at $0.33, and the highest EPS forecast at $2.47. In 2027, TLX's EPS is forecast to hit $0.72 (min: $0.33, max: $1.25).

What is TLX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: TLX) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.